Parkinson's disease gene therapy - Oxford BioMedica

Drug Profile

Parkinson's disease gene therapy - Oxford BioMedica

Alternative Names: OXB-101; OXB-102; ProSavin; Tricistronic lentiviral vector encoding for TH, AADC and CH1 - Oxford BioMedica

Latest Information Update: 21 Sep 2015

Price : $50

At a glance

  • Originator Oxford BioMedica
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Dopamine release stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Parkinson's disease

Most Recent Events

  • 21 Sep 2015 Phase-I/II development for Parkinson's disease completed in France and the United Kingdom
  • 13 Mar 2015 Oxford BioMedica plans a phase I/II trial of OXB 102 for Parkinson's disease in United Kingdom
  • 05 May 2014 Oxford BioMedica receives a grant from the UK's Technology Strategy Board, under its Biomedical Catalyst funding programme, for Parkinson's disease gene therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top